Immunic Shares Outstanding History (IMUX)
Immunic reported 90.2M shares outstanding at the end of fiscal 2025.
View full Immunic company overviewImmunic annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 90.2M | 0 | 0.00% |
| 2024 | 2024-12-31 | 90.2M | 45.0M | +99.55% |
| 2023 | 2023-12-31 | 45.2M | 5.9M | +14.93% |
| 2022 | 2022-12-31 | 39.3M | 13.0M | +49.26% |
| 2021 | 2021-12-31 | 26.3M | 5.2M | +24.41% |
| 2020 | 2020-12-31 | 21.2M | 10.4M | +97.01% |
| 2019 | 2019-12-31 | 10.7M | 9.9M | +1168.64% |
| 2018 | 2018-12-31 | 846,953 | −212,268.6 | −20.04% |
| 2017 | 2017-12-31 | 1.1M | 255,634.725 | +31.81% |
| 2016 | 2016-12-31 | 803,586.875 | 41,759.8 | +5.48% |
| 2015 | 2015-12-31 | 761,827.075 | 162,257.425 | +27.06% |
| 2014 | 2014-12-31 | 599,569.65 | 584,413.7 | +3856.00% |
| 2013 | 2013-12-31 | 15,155.95 | — | — |
Immunic quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 13.6M | −85.0M | −86.17% |
| Q1 2026 | 2026-03-31 | 13.6M | −76.5M | −84.89% |
| Q4 2025 | 2025-12-31 | 12.0M | −78.1M | −86.65% |
| Q3 2025 | 2025-09-30 | 98.7M | 8.6M | +9.52% |
| Q2 2025 | 2025-06-30 | 98.7M | 8.6M | +9.52% |
| Q1 2025 | 2025-03-31 | 90.2M | 71,853 | +0.08% |
| Q4 2024 | 2024-12-31 | 90.2M | 45.0M | +99.55% |
| Q3 2024 | 2024-09-30 | 90.1M | 45.5M | +101.99% |
| Q2 2024 | 2024-06-30 | 90.1M | 45.6M | +102.48% |
| Q1 2024 | 2024-03-31 | 90.1M | 45.7M | +102.86% |
| Q4 2023 | 2023-12-31 | 45.2M | 5.9M | +14.93% |
| Q3 2023 | 2023-09-30 | 44.6M | 14.0M | +45.90% |
| Q2 2023 | 2023-06-30 | 44.5M | 13.9M | +45.55% |
| Q1 2023 | 2023-03-31 | 44.4M | 15.2M | +51.86% |
| Q4 2022 | 2022-12-31 | 39.3M | 13.0M | +49.26% |
| Q3 2022 | 2022-09-30 | 30.6M | 4.3M | +16.44% |
| Q2 2022 | 2022-06-30 | 30.6M | 8.8M | +40.53% |
| Q1 2022 | 2022-03-31 | 29.2M | 7.5M | +34.44% |
| Q4 2021 | 2021-12-31 | 26.3M | 5.2M | +24.41% |
| Q3 2021 | 2021-09-30 | 26.2M | 5.5M | +26.70% |
| Q2 2021 | 2021-06-30 | 21.7M | 6.8M | +45.30% |
| Q1 2021 | 2021-03-31 | 21.7M | 10.9M | +100.95% |
| Q4 2020 | 2020-12-31 | 21.2M | 10.4M | +97.01% |
| Q3 2020 | 2020-09-30 | 20.7M | 10.6M | +105.73% |
| Q2 2020 | 2020-06-30 | 15.0M | 5.0M | +49.89% |
| Q1 2020 | 2020-03-31 | 10.8M | 9.8M | +921.82% |
| Q4 2019 | 2019-12-31 | 10.7M | 9.7M | +914.41% |
| Q3 2019 | 2019-09-30 | 10.1M | 9.0M | +850.74% |
| Q2 2019 | 2019-06-30 | 10.0M | 8.9M | +842.80% |
| Q1 2019 | 2019-03-31 | 1.1M | 20.75 | +0.00% |
| Q4 2018 | 2018-12-31 | 1.1M | 0 | 0.00% |
| Q3 2018 | 2018-09-30 | 1.1M | 4,057.95 | +0.38% |
| Q2 2018 | 2018-06-30 | 1.1M | 4,040.55 | +0.38% |
| Q1 2018 | 2018-03-31 | 1.1M | 4,037.2 | +0.38% |
| Q4 2017 | 2017-12-31 | 1.1M | 255,634.725 | +31.81% |
| Q3 2017 | 2017-09-30 | 1.1M | 256,463.025 | +32.11% |
| Q2 2017 | 2017-06-30 | 1.1M | 266,706.625 | +33.83% |
| Q1 2017 | 2017-03-31 | 1.1M | 280,679.875 | +36.24% |
| Q4 2016 | 2016-12-31 | 803,586.875 | 41,759.8 | +5.48% |
| Q3 2016 | 2016-09-30 | 798,721.375 | 195,079.375 | +32.32% |
| Q2 2016 | 2016-06-30 | 788,477.775 | 188,116.425 | +31.33% |
| Q1 2016 | 2016-03-31 | 774,504.525 | 174,934.875 | +29.18% |
| Q4 2015 | 2015-12-31 | 761,827.075 | 162,257.425 | +27.06% |
| Q3 2015 | 2015-09-30 | 603,642 | 58,870.4 | +10.81% |
| Q2 2015 | 2015-06-30 | 600,361.35 | 55,592.725 | +10.20% |
| Q1 2015 | 2015-03-31 | 599,569.65 | 584,413.7 | +3856.00% |
| Q4 2014 | 2014-12-31 | 599,569.65 | 584,413.7 | +3856.00% |
| Q3 2014 | 2014-09-30 | 544,771.6 | — | — |
| Q2 2014 | 2014-06-30 | 544,768.625 | — | — |
| Q1 2014 | 2014-03-31 | 15,155.95 | — | — |
| Q4 2013 | 2013-12-31 | 15,155.95 | — | — |
Immunic shares outstanding trends
Over the last five reported fiscal years, Immunic's shares outstanding moved from 21.2M to 90.2M, a change of 69.0M. The latest reported quarter, Q2 2026, shows 13.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunic filings at SEC.gov ↗